CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-14 | Bhanji Muna Director | Grant or award · Stock Option (right to buy) | +6,473 | 6,473 | ||
| 2023-04-14 | CHASE WILLIAM J Director | Grant or award | +10,483 | 17,283 | ||
| 2023-04-14 | CHASE WILLIAM J Director | Grant or award · Stock Option (Right to Buy) | +14,931 | 14,931 | ||
| 2023-03-02 | BASTA JAMES EVP, General Counsel | Sale | −1,088 | $43.88 | $48K | 55,279 |
| 2023-03-01 | Hicks Derek EVP, Chief Business Officer | Grant or award | +23,558 | 40,864 | ||
| 2023-03-01 | Hicks Derek EVP, Chief Business Officer | Grant or award · Stock option (right to buy) | +33,287 | 33,287 | ||
| 2023-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award | +27,484 | 42,888 | ||
| 2023-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +38,834 | 38,834 | ||
| 2023-03-01 | LEONARD JOHN M President and CEO | Grant or award | +91,036 | 857,861 | ||
| 2023-03-01 | LEONARD JOHN M President and CEO | Grant or award · Stock Option (right to buy) | +128,631 | 128,631 | ||
| 2023-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +30,674 | 56,361 | ||
| 2023-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +43,342 | 43,342 | ||
| 2023-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award | +29,938 | 47,567 | ||
| 2023-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +42,302 | 42,302 | ||
| 2023-03-01 | Clark Eliana EVP, Chief Technical Officer | Grant or award | +24,539 | 39,012 | ||
| 2023-03-01 | Clark Eliana EVP, Chief Technical Officer | Grant or award | +6,134 | 45,146 | ||
| 2023-03-01 | Clark Eliana EVP, Chief Technical Officer | Grant or award · Stock Option (right to buy) | +34,674 | 34,674 | ||
| 2023-03-01 | BASTA JAMES EVP, General Counsel | Grant or award | +24,539 | 44,098 | ||
| 2023-03-01 | BASTA JAMES EVP, General Counsel | Grant or award | +12,269 | 56,367 | ||
| 2023-03-01 | BASTA JAMES EVP, General Counsel | Grant or award · Stock Option (right to buy) | +34,674 | 34,674 |
Page 10 of 40 · 783 trades